What question did this study set out to answer?

This analysis aims to compare the bioavailability and clinical efficacy of Ayurvedic Churna and Vati dosage forms.

April 1, 2026Open Access

Bioavailability vs Convenience: A Comparative Pharmaceutico-Clinical Analysis of Churna (Powder) and Vati (Tablet) Dosage Forms in Ayurvedic Therapeutics

Key Points

This analysis aims to compare the bioavailability and clinical efficacy of Ayurvedic Churna and Vati dosage forms.
Conducted a comparative analysis of pharmacodynamics and pharmacokinetics of Churna and Vati.
Investigated the impact of tablet compression and excipients on therapeutic outcomes.
Analyzed the effects of oral sensory signaling on the bioavailability of both forms.
Tablet form (Vati) shows reduced bioavailability compared to powder (Churna).
Findings indicate a significant loss of therapeutic potency in tablets for certain indications.
Clinical outcomes for Deepana and Pachana are compromised with Vati dosage form.

Abstract

The modernization of Ayurvedic pharmaceutics has seen a massive shift from traditional powders (Churna) to compressed tablets (Vati/Gutika), driven primarily by patient compliance and convenience. However, this shift raises critical pharmacokinetic questions regarding efficacy, onset of action, and bioavailability. This paper analyzes the comparative pharmacodynamics of Churna and Vati, exploring the "Convenience Tax"—the potential loss of therapeutic potency due to compression, excipients, and the bypassing of oral sensory signaling (Rasa-Bodhana). We argue that for specific therapeutic indications, particularly Deepana (appetizer) and Pachana (digestive), the tablet form significantly compromises clinical outcomes.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper